Prevalence and risk factors of nonalcoholic fatty liver disease in patients with chronic hepatitis B receiving antiviral therapy
10.3760/cma.j.issn.1007-3418.2019.05.005
- VernacularTitle: 接受抗病毒治疗的慢性乙型肝炎患者非酒精性脂肪性肝病的患病率及其危险因素分析
- Author:
Hui GAO
1
;
Zhe KUANG
;
Chunxiu ZHONG
;
Xieer LIANG
;
Rong FAN
;
Kaifeng WANG
;
Weiyin LIN
;
Jinlin HOU
;
Jian SUN
Author Information
1. State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
- Publication Type:Journal Article
- Keywords:
Fatty liver, non-alcoholic;
Hepatitis B;
Prevalence
- From:
Chinese Journal of Hepatology
2019;27(5):347-351
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prevalence and risk factors of non-alcoholic fatty liver disease(NAFLD) in patients with chronic hepatitis B(CHB) receiving antiviral treatment.
Methods:The cross-sectional study included 3 477 cases with CHB who received antiviral therapy. The prevalence of NAFLD was investigated, and then the risk factors were screened and analyzed by stepwise regression method in CHB patients with NAFLD as the dependent variable and the related influencing factors as independent variables.
Results:The prevalence of NAFLD was 24.1% in CHB patients who received antiviral therapy. After adjusting for age and gender, central obesity (OR: 7.44, 95%CI: 6.06 ~ 9.14), hypertension (OR: 1.74, 95%CI: 1.51 ~ 2.20), and triglyceride (OR: 1.52, 95%CI: 1.18 ~ 1.96) were positively associated with NAFLD, and cirrhosis was negatively associated with NAFLD (OR: 0.42, 95%CI: 0.34 ~ 0.53). Patients with long-term antiviral therapy had increased risk of NAFLD.
Conclusion:A significant proportion of CHB patients receiving antiviral therapy have suffered from NAFLD. Therefore, CHB patients receiving long-term antiviral treatment should pay more attention to the prevalence of NAFLD.
